The imaging study is being led by the Purdue University Center for Cancer Research and performed at the Department of Urology at the Indiana University School of Medicine. Detailed results of this study are anticipated to be presented at an upcoming medical conference.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
For additional information, please visit Endocyte's website at
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to future regulatory filings, development of effective targeting ligands, and expansion of Endocyte's SMDC platform. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that could cause such a difference include risks of delays in conducting studies required for regulatory filings (which delays might be caused, for example, by unanticipated challenges in manufacturing compounds on the scale necessary to conduct such studies), technical and scientific risks associated with developing targeting ligands with superior specificity or other characteristics, and risks related to the safety and efficacy of Endocyte's product candidates. More information about the risks and uncertainties faced by Endocyte is contained in its periodic reports filed with the Securities and Exchange Commission. Endocyte disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc.,
(212) 362-1200, email@example.com
Martina Schwarzkopf, Ph.D., Russo Partners,
(212) 845-4292, firstname.lastname@example.org
Tony Russo, Ph.D., Russo Partners,
(212) 845-4251, email@example.com